youngster from here with him each time going to could tar is 16 year old park. you been they are hung ever. i've been to a lot of local games, but this will be the 1st time abroad, so i will cheer extra heart model whether the take of warriors progress from the group stage park will have to be back in 10 days. his business and his marriage, he says we can't afford more or cut that wall. doctor. my wife told me to sign the divorce papers before i go to carter, but i told her, i'll do it when i get back, because i know i can change your mind when i return brought the price some pay for the love of the game. robert bride al jazeera de john south korea. ah, you're watching out his era. these are the headlines this hour. the kremlin says vladimir putin is open to talks about the so called special military operation in

ukraine. but warned washington stance on territory under its control would make negotiations difficult food. and hans recently spoken on the phone with the german chancellor, all of sholtes, the u. s. president said on thursday he is willing to meet with bruton, if he and if the conflict mohammed val has more from moscow. the spokesman of the kremlin mitre prescott, he said that putting has always been open for negotiations with regards to ukraine . but the understanding from his words is that there is a kind of precondition in what the president biden said, which is that russia should be ready to withdraw from ukraine. and he said, bats makes thinks very difficult. and us bank group that helped to fade isis in syria has stopped all joint counterterrorism operations. the syrian democratic forces say it's a result of turkish bombardment of territory. it controls chicky has stepped up,

strikes in northern syria since of bombing and assemble last month. israel has ordered the deportation of a palestinian french lawyer from occupied east jerusalem fella. maury has been detained since march without charge or trial. south africa, main opposition party says its table motion to dissolve parliament in order to hold early elections. it comes after an independent panel found president cyril ram, oppose, and may have violated his oil of office. he denies any wrongdoing and a routine session in senegal, parliament has descended into violence. fighting began on thursday when a man politician was after a female colleague and flapped her in. the face tension has been growing between the government and opposition since the ruling party lost its majority in july. all right, those are the headlines i'm emily. angling. the news continues here, announces era after inside story

ah, a new drug is being touted as a breakthrough to find a cure for alzheimer's. it's the 1st treatment to slow the onset of the degenerative disease, but it's not without risk. so how important is this trial and what will its impact be on millions. this is insightful. ah hello and welcome to the program. i'm how much am john? japanese and american pharmaceutical companies have published the results of

a trial which is being held as a breakthrough in the fight against alzheimer's disease. the data showed how a new drug can significantly slow down cognitive decline in some patients by 27 percent. the 18 month trial involved nearly 2000 participants who were in the early stages of the illness. health experts say one person develops dementia every 3 seconds. alzheimer's is the most common cause of dementia. the number of people suffering from the disease is expected to double every 20 years. worldwide. dementia costs are more than a trillion dollars globally, about a 3rd of the u. k. 's annual g d p. those figures include direct medical care and social and unpaid costs. and early detection of neuro degenerative disorders is crucial for recognizing signs of alzheimer's or cognitive decline will bring in our guests in a moment. but 1st, this report from harry faucet in london for over 30 years. scientists have tried and failed to design a drug that tackles the cause, not the symptoms of alzheimer's disease. now comes the 1st evidence of real success

and antibody infusion that attacks a specific protein in the brain. slowing the development of early stage alzheimer's by around a quarter professor john hardy, 1st develop the theory of it. we said that this approach might work 30 years ago. and you know, if you'd asked me 30 years ago how long it would take, i'd say 5 to 10 years. so for me it's, it seems definitely momentous. i think for patients, it's a real step forward, a real step forward. and it's going to take a couple of years to get it into the system. it's patients like john teeling in the early stages of the disease who stand to benefit the most. john says he felt the ground open up when he was diagnosed. he'd embrace anything that gives him more time with his wife and family. you put him on, you know what your grand, upright and you know, the channels that you can do about it. but you can't worry about it because there's

no way you can do someone be accepting of it. the new drug laquanda mab inhibits the build up in the brain of a protein called b to amyloid visible is so called plaques. in the brains of alzheimer's patients. nearly $1800.00 patients around the world took part in the study which showed a 27 percent slow down in the deterioration of their cognitive skills over 18 months. but it's approved. the treatment will be laborious and costly to administer through blood infusions twice a month. and will also require major investment in screening for the disease to catch it sufficiently early. and at the moment we do that through pet scans or drink cerebral final testing for from a lumber puncher. and that is we need to broaden access to ways in which we can have access to those kind of test. we also want to see new techniques that are quicker and faster and potentially cheaper. for example, blotter, 30000000 people around the world. subtle without highness in itself,

just one form of dementia. much difficult and costly work remains before treatments . that loan cures a widely available. but this is a hugely significant 1st step. harris will sit al jazeera london. ah. all right, let's go ahead and bring in our guests in glasgow. graham sutherland, who uses social media to raise awareness about all timers after his mother was diagnosed. he's also a social media ambassador for all timers, scotland, and live in belgium. dr. bart, this trooper director of the u. k. dementia research institute and in cambridge, susan cole, hoss director of research at alzheimer's research. u. k. a warm welcome to you all and thanks so much for joining us on. and so i story today as susan, cool hoss, let me start with you today. the results that have been released thus far from this clinical trial of the kind of how big a breakthrough is this? this is a historic moment for all 3 years because it's the 1st time that we've actually

shown that a drop that you give to people can low cost to decline. and really what we've been waiting for the field for many, many years. and it's a combination of many years of research, patient effort, and people participating in clinical trials is fantastic news for the field. it shows that dimension is simply an ethical age and we're really need to lie to our research u. k. and just call has let me also just follow up with you. i mean, you mentioned that this is showing that it was, that is slowing cognitive decline. this clinical trial found that after 18 months, patients receiving kind of mob declined slower than those taking a placebo. that difference is that enough to be considered a clinic clinically meaningful treatment. we don't really have consensus on that the moment, but there are a couple of big unknown. i think 1st is this, this drug is gives a modest effect. i think it's really important to manage people's expectations on

that, but this is a 1st generation drug and we wouldn't, wouldn't normally see major impact for 1st generation drug. i think the 2nd thing to remember is that for somebody who is developing all timers disease in the early stages, the goal howard's disease was meaningful could be really different. give people more time when their families to people more times live independently. and i think that is not to be understated for a patient community that has waited for decades for treatments. and i think finally, we don't have yet because it's too early, long term day. so whether intervention or early or can actually change the trajectory of the disease later on. those studies of the long term studies are reflect that they, the long term will be really he and determining whether or not we see effects much

longer than the 18 months that we, we've studied, stay in groups, havilland. i saw you nodding along to some of what susan cole hoss was saying there, and i want to ask you if someone who has very publicly documented the tool that alzheimers has taken on your mother and on your family. what was your initial reaction when you heard the news about the results of this trial? because it does get some hope for the future for people whose family loved ones diagnosed with the disease. because when my mom was diagnosed by that wasn't edison, i hope so. defeats kind of sealed about point, which is at least a path and direction. and graham, how long ago was your mother diagnosed? and what kind of a told that take finding that out for you and for her and for other members of your family. so she was diagnosed over 70 years ago now and it's been quite slow, but more sped up more recently. and i think the tool has been very,

has go to, but mainly i meant to impact because you're, you're watching your loved one. i'm watching my mom a. ready sophie, the, we in front of me as affected all the family and friends watching that happen because there's nothing you can do. ready you feel very was and you know, you need to take care of i guessing because there's not a lot of funding in place to help caters and a lot. ready lake, my cell from us, the house in waste to do with thought bart, to super this approach to treating alzheimer's. this has been in the works of i understand it for over 30 years. why did it take this long and, and what's the difference between this form of treatment and other forms of treatment that have been attempted in the past? and that's a big question. you know, so 1st of all, why does it take so long? i think the brain is one of the most difficult, but i think that we all agree that it's a very difficult organ, much more difficult than anything else we study. there's also,

it's also very protected from an environment, so that means it's getting medication in the brain. it's very difficult. but if you really ask me why it has taken so long, i think it's because the street has huge be being underfunded, overall is yours. and. and i think that that if you, if you compare each for instance, if you'd like cancer where we have seen a lot of progress, i think it's a 15 folds difference. so it just takes much more time to get your money together to do your investigations that do best things. so that's for me to, to reasons. it's a great difficult problem. and it's an understanding things. and the, and the ways org saying and how it compares. we dollars, so the genetic proof that i'm a large is i can, relation in the brain are closely related to disease has been there for many years . but because i was trying, i was trying to tackle each failing. there was

a lot of criticism and people started to think that it was not the right way. so it's for scientists slightly, a very satisfied buying to see that you are always years on the right track in that a b have it's a necessity and you want to achieve something so adamant. are there other ways to prevent possible? i think that we need to find other ways to bust those. i mean, are blacks because a drug that you have now is far too expensive. if you want to grow up and go over the for the, for the big 5000000 people with dementia, i went down to steve to meet him in 30 years. we need to have it as cheap. so that's the challenge now for the people in this area. and so we can talking about other examples, but i'll say it is also characterized by other allegiance, for instance. and the names on those are important, but they only diagnose and there's also a kind of inflammation in the brain and you start to understand those of those

pathologies better and better. and so obviously retired and also similar busters as, as the amazon drink. we have now that would be extremely helpful. and so, and so thus i am at, but that is the nice thing. now we have a breakthrough. and so it will be much easier now to best the wide. he said to, to, to go or go this through that you can do something about this disease. and bart, the super i just wanted drill down on, on something you mentioned that cause you were, you were mentioning this word amyloid in this new drug like panama. it's an antibody and, and it inhibits that build up in the brain of this protein called beta emily. now i don't know how it works, to be honest. okay, what was wondering if we can just briefly explain the lives if we just explain to our viewers what exactly is beta amyloid and what role does that play? yeah, well um to make it short so and our body produces all kinds of

proteins which are basically the, the legal machinery to everything which you do all the days thinking, working, etc. and so the 1st small building blocks and so that i'm a lot of petrified is a small fragment or such ability book building global goals. they logically, i'm united precursor and so and a small fragment of ducks, i'm glad because it is, i'm a diabetic light. you can see there's a small piece that breaks up over storm over over of soak, and that smoke base accumulation. the brain goes problem is there, and that's go on black. sure. i'm on the back side. is small pieces accumulating under the form of the blades. and the things in the dream, i saw you nodding along a bit when bart was talking about the fact that from his perspective, one of the reasons it's taking this long to get where we are right now is because the research into alzheimer's has been underfunded. do you think that the results

of this clinical trial will spur more funding will will this fight be better funded, going forward hopefully, because as, as she said, that this is like concert is betty mainstream. and i'll say most as betty betty underfunded and not really spoken about as much is all will are listed on cancer, has a lot of cures, 2 treatments. it is our team has had, has had nothing them to know. so what for us as a thought of something that can be spoken about more and more awarenesses based to be able to raise more money in funds for the future is this isn't co hossa of course the early detection of neuro degenerative disorders. it's crucial for recognizing signs of, of all timers or, or recognizing signs of cognitive decline overall. do you think we're going to see more breakthroughs on this front? i think we have to we're now on the present system having our 1st

generation of treatment that can flow disease processes. but there is no good unless we can start to identify and treat people early. we've seen a number of breakthroughs in the field that have been a little bit less high profile than this one over the years, starting to look at different different n cheaper ways of identifying people who have the pathology in the brain associated with all hours disease. so measuring the ability to measure in the blood for example, build up of amyloid is how and i think what we really need to do in the field is focus on how we get people diagnosed early into the clinic. offer access to drums when they finally do come through the regulatory crisis. also get them involved in research thing is that once in a lifetime, opportunity to take this breakthrough and actually turn it into more discoveries.

what happens when we look lower, analyze in the brain? what are the other processes that are growing on? how can we start to target those? it's important to remember that there are over a 140 different treatments in clinical trials right now for all disease. most of those are not for amyloid. and i think it's probably this era of starting to think about what would combination treatment look like. and how would we data a feels that will read a shift to dialogue over able to de bar to super. i saw you nodding along to some of what susan was saying there, it looks like you wanted to jump in, so please go ahead. oh no, i just agreed to be speech to previous speakers. i think getting away from that, which is the wrench. it's crucial that you want a society said that i mentioned go wholly not going to talk a lot about it today but,

but this is really essential that our government responsible people started to think how we are going to organize us. because he's just, he's not going to mean that he's all of a sudden no people he dementia anymore. so there will be big. ready small benevita curve and we will have to work hard to get new trucks. i usually get companies to meet with 8 because people remember that this was a disease for me, not cure center and beginning we didn't really know how to do it. and then there was a drug which war but not from plastic. and then he got better and better drugs and nowadays week we haven't queued for that for the, for that these are the. so i think that's, that is about that binds brain. we will see now for, for alzheimer's and we'll see that who improvements. and so we need to think both about about investing, researching best thing you cures, and also investing in good care and a good diagnosis of the patients who need to,

to start today that in a professional way. and then a lot of point i also want to make because it is a lot of confusion about dementia outside of motor and so on. so didn't know majority disorders. and so you have all sound which have also, but can some disease you have also. i mean, i mean, you're totally globe and i was there was a demo the same principle of all or disease. so i expect that to see very soon also breakthroughs in these other areas based on the success maker. and it's very important also to realize that many people reach out diagnosed symes, have mixed forms of literally duration. so it's not all the one process which is going on, but 2 or 3. and so the importance to get who brought in our portfolio and to do further did basic research. because that's usually not mentioned at all. but it's a big research which has made this possible and is a big research which will make it possible to pin or not. so that's something that

important doesn't message green. we ran a report earlier in the show from my colleague harry faucet, and he said in his report that if this treatment is approved, it's going to be expensive. it's going to be difficult to administer. patients are going to need blood transfusions as i understand it twice a month. first of all, from your perspective, how difficult might it be for patients to actually get this treatment when and if it's approved. and are you concerned that this treatment is going to be too expensive to become widely available? yeah, so it could cause issues. i mean, from my mom's perspective, to a lot of that kind of any teams and, and, but even get them to conic or any of us to administer the treatment would be very difficult. and the cost is already very difficult for my care off of them to be able to afford things because a lot of caters, are giving up their jobs and the all of the homeless they're paying. ready to cost

them so i don't know where they're going to get the money from to do that. or as a government people, i would be very expensive. sure. i don't know where they get funding, which is my motor way on. this needs to be raised for it to be able to raise those funds for people. great. may i ask it because you have been so public and so open about what it's been like for you and your family to deal with alzheimer's. if you had been told earlier on in the course of this disease, that your mother suffering from that this might have been a viable option. how would you have felt to think that you might have been able to get that extra time? i mean, what, what does the potential of this mean for those who are just now hearing about a diagnosis about potentially getting a little bit of extra time with a relative if, if this drug is ultimately approved as that the employee pays team his team has been taken away from his family and moments whenever the expedients, so even if it saves some payments as tame that we need. and we had the option then

definitely look into it and do what we could to get it. i think. but it also was said effects. the the said the face could be. ready ready made by the, the positives off, off struck if it does save time, if it goes what farm we spend more time to get our key won't even just have life events together that may not be able to experience. and we don't know how long each stage last and i'll say must so like my mom can't speak very much anymore, so would be laces. even that tainted can back on you to be able to speak to me and know who i was it. the pathos, susan, cause you heard graham there, talk about the fact that there are side effects and experts have already warned about potential side effects from, from this drug. what are some of the side effects? what are some of the concerns going forward? i think the main side effect that many people are concerned about is something

called which is welling and or micro leads on the brain. and i think it's really important to note that this drug hasn't been through regulatory approval yet. i think the next step before it becomes more widely available that it needs to go and get regulatory approval. and i think regulate in different countries will look at those side effects in detail and way the effectiveness of the drug goals or the safety profile of the drug, and provide some recommendations about or, or even conditions about how it could be used and what monitoring people would need to go through in order to access the drug. but then just to just make a couple of like one of one of the things for people to remember. it's not blood transfusions that people latest infusion, sorry, going to hospital for an hour and i haven't drugged, put on a trip and have to drug it put into your system that way. right. and

or it's a very easy when things are right. and i think the other thing that people should be aware of each country will have it for deciding how the drug should be given and how much you know, whether, whether it's subsidized or paid for by that countries help. and so the conversations between the company and each of the different countries haven't started yet, and we don't have any information on exactly what the drug would cost or how it would be administered. but i think it's fair to say that in most countries, certainly in the u. k. d, and i said, it's not ready to deliver this drug. and the time is now to get government charity clinicians and people affected by all timers, disease together to work out how we make ready to deliver treatment at large, not just specific treatment. we don't want to lose any time to do that

because the research effort had been put in. and we want to make sure people can benefit as quickly as possible. graham, if there's one message you'd, you'd like to give to viewers out there about what, what, what kind of a toll this disease takes on families on individuals. what would that be and is completely changed, and it stills so much from you. and, and i just think a lot of people think buses are passing, who's very old gets, as opposed to my mom was early onset and becoming younger. so it's something that's become another problem. and the younger, younger on people need to speak more about to be more spoken about and like my cell criteria as much as possible because as life changing, it does affect everson. my life is made me grow very quickly because my mom is more with it at my age. it just has

a. ready mentor for school tool on you and. ready families can change it. all right, well we have run out of times, we're going to have to leave our conversation there. thanks so much. all of our guests. graham, sutherland bar to stripper and susan cole house. and thank you to for watching. you can see the program again, any time for visiting our website, algebra dot com. and for further discussion, go to our facebook page. that's facebook dot com, forward slash ag inside story. you can also do the conversation on twitter or handle it at a time story for me, how much i'm driven, holding here until 5 in the ah

a as officially begun and goes ahead to 3 stadium by the metro i stuff with offices to see how easy it is a to celebrate a bo this feels like a big noise and it's sort of thursday that is hugely important. so not only the visitors, but also those of us who live here at lou sales stadium where the world cup final is gonna be held in time. on monday with join the debate. when we talk about climate change in africa, we should focus on adaptation knocked mitigation on our online, at your voice. they shouldn't be exploiting like what,

what not is being right now is being everything that is going to benefit them more revealing new perspectives. like getting this out of proportion. no, no, his region has power is what is this proportionate? the stream we're a global audience becomes a global community on al jazeera reporting in the field means i often get to witness not just news as it's breaking, but also history, as it's unfolding. dropping from serbia hungry to rep, monday, i might be covering politics. and then actually i might be covering photos, but what's most important to me is talking to people, understanding what they're going through so that i can convey the headlines in the most human way possible. here at al jazeera, we believe everyone has a story worth hearing. a new series, exploring how traditional knowledge from indigenous community is helping tackle to these environmental catastrophe. we journey across new mexico and meet those who

fight to protect their culture and raise awareness of the impact of climate change and pollution on their secret land. first nations frontline meet of nation voices of survival analogies. ah, are you watching al jazeera, i'm so robin into her with all top news stories. the kremlin says vladimir putin is open to talks about the so called special military operation, ukraine. but ward washington stands on territory under its control would make negotiations difficult. putin has recently spoke on the phone with the german chancellor of shells. us president joe biden, you said on thursday that he's willing to meet putin if he ends. the conflict ma'am at val has more for moscow.